This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

​EU announces clearance of BMS' acquisition of Celgene

( July 30, 2019, 10:43 GMT | Official Statement) -- MLex Summary: The European Commission has said it granted merger clearance for Bristol-Myers Squibb Company's acquisition of Celgene. The companies' activities overlapped on the markets for marketed and pipeline products in autoimmune diseases, oncology and fibrotic diseases. The commission approved the deal because of the number of actual and potential competitors, and its limited impact on markets.Statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login